Supplement · graded by use, four uses
Taurine
Acute exercise performance (3km running time).
Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →
Taurine is a building block found in meat and fish, and in energy drinks. In three studies of people with type 2 diabetes, taurine improved blood tests linked to blood vessel health and swelling. Those tests are not proof that people stay healthier. Small studies also looked at blood sugar and at running time, with modest results. No study shows that taurine helps people live longer.
The C belongs to one of the four uses graded on this record. The other three carry their own letters.
As studied, and the trials
Animal and observational Research that watches what people already do rather than assigning a treatment. It can show that two things travel together, not that one causes the other. evidence only for the aging claim; the small randomized trials in older women (Abud 2022; PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 35700594; Chupel 2021; PMID 33586039) measured markers and fitness, and the one trial reporting mortality (Van Stijn 2015; PMID 26035756) was a week-long perioperative course around hip fracture surgery, null. The premise behind the aging claim has also failed a direct test: Fernandez et al. (Science, 2025; PMID 40472098), from the National Institute on Aging, found circulating taurine rose or held steady with age in three human cohorts, in monkeys and in mice, measured both in the same people over time and across age groups. A later observational study found no association between circulating taurine and age or physical performance in 137 men (Marcangeli et al., 2025; PMID 41061678).
As studied, and the trials
Balshaw et al. (Amino Acids, 2013; PMID 22855206) is a double-blind Neither the participants nor the people assessing them know who received the real treatment until the trial ends., randomized, crossover trial of acute taurine ingestion in trained middle-distance runners. A human randomized trial has been run on this endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. and found a benefit, which is why this use carries a C while the aging use, which no trial has tested, is D on Route 1 No human randomized trial has been run, so the record rests on animal or mechanistic evidence only. One of the two routes to the lowest letter on EBL's scale.. The two are not the same claim. Pooled analyses of acute taurine on broader endurance performance find small effects: Waldron et al. (2018; PMID 29546641), 10 studies, g 0.40; Deng et al. (2025; PMID 40852891), 23 trials, g 0.25, certainty low to very low. Nobody has repeated the 3-km trial.
As studied, and the trials
Moludi et al. (Nutr Metab (Lond), 2022; PMID 35870947): 120 adults with type 2 diabetes, 3 g/day for 8 weeks with a low-calorie diet in both arms; fasting glucose, named as a primary outcome, did not improve, nor did HbA1c A blood test that reflects average blood sugar over the previous two to three months.. Maleki et al. (Amino Acids, 2020; PMID 32472292): 45 adults with type 2 diabetes in Tabriz, 3 g/day for 8 weeks without a diet; fasting glucose, insulin, HOMA-IR, total and LDL Low-density lipoprotein cholesterol, the cholesterol fraction most closely tied to plaque in the arteries. cholesterol fell against placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received., HbA1c did not. Esmaeili et al. (Can J Diabetes, 2021; PMID 32861603): 46 adults, 3 g/day for 8 weeks, from the same Tabriz group and likely overlapping; fasting glucose, HbA1c, insulin and HOMA-IR fell. Pooled analyses find small reductions in fasting glucose: Tzang et al. (Nutr Diabetes, 2024; PMID 38755142) and Nie et al. (Nutr Rev, 2026; PMID 41275513), with 1.5 to 3 g/day for 8 weeks or longer most effective. One null trial and one positive group of trials at the same dose, with pooled small effects: mixed randomized evidence on a surrogate is C, not D on Route 2 Human randomized trials have been run and did not show benefit on the stated outcome. One of the two routes to the lowest letter on EBL's scale..
As studied, and the trials
Three independent randomized placebo-controlled trials in type 2 diabetes point the same way. Moludi et al. (Nutr Metab (Lond), 2022; PMID 35870947): 120 adults, 3 g/day for 8 weeks; endothelial adhesion markers, hs-CRP High-sensitivity C-reactive protein, a blood marker of low-grade inflammation. and TNF fell. Maleki et al. (Diabetol Metab Syndr, 2020; PMID 32015761): 50 adults in Tabriz, 1 g three times daily for 8 weeks; hs-CRP, TNF-alpha and malondialdehyde fell, superoxide dismutase and catalase rose. Li et al. (iScience, 2025; PMID 40546935): 165 adults in Chongqing, 2.4 g/day for 12 weeks, double-blind; systolic blood pressure fell and endothelium-dependent vasodilation and pulse wave velocity improved. Circulating and vascular surrogates, not clinical events, which caps the letter at B; replication The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away. across three groups reaches it. The Tabriz and Kermanshah trials share a national research setting and the Tabriz group has overlapping cohorts across its papers, so the Chongqing trial is the independent replication that matters. Nie et al. (Nutr Rev, 2026; PMID 41275513) pool the inflammatory and oxidative markers across taurine trials, with malondialdehyde lower (SMD -1.16) and 1.5 to 3 g/day the most effective range. PubMed does not yet index the three trials as randomized, so the pooled analysis is the indexed synthesis the letter can point to. These are circulating and vascular markers, none an established stand-in for a clinical outcome, so under the B definition the agreement of three trials reaches C, not B.
Read the grade that matches your goal. How EBL grades by use →
A letter describes the human evidence, not the product, the manufacturer, or the ingredient's worth.
See the full evidence record →Endothelial and inflammatory markers in type 2 diabetes: three independent randomized trials, circulating and vascular surrogates.
Grade scope · Grade C overall, following the best-supported use. Endothelial and inflammatory markers in type 2 diabetes are Grade C: three independent randomized trials (Moludi 2022, PMID 35870947; Maleki 2020, PMID 32015761; Li 2025, PMID 40546935) found the same direction, but these markers are not established stand-ins for a clinical outcome. Glycemic control in type 2 diabetes is Grade C, on one null and two positive trials at 3 g/day. Acute exercise performance is Grade C (Balshaw, Amino Acids 2013, a randomized crossover trial in eight trained middle-distance runners, found a 1.7% improvement in 3 km time from a single acute dose, and nobody has independently repeated it). The aging and longevity claim is Grade D on Route 1, animal and observational evidence only, and the taurine-declines-with-age premise failed replication in 2025.
As studied: dose, form, population and duration for every use
A grade describes the intervention that was tested. Where the product on the shelf differs from it, this says so.
The trial that would change this grade.
Positive trials of this shape from independent research groups would move this entry to A.
Why the current trials fall short
The headline C rests on vascular and inflammatory surrogates in type 2 diabetes. Hard-outcome trials from independent research groups would move the headline to A; the longevity claim, which rests on animal work and observational human data, would move from D to C on any adequately sized randomized trial with a clinical endpoint.
Why people believe itTwo human sources; one published case report of benefit; no reports of harm.
The case for taurine rests on a 2023 study showing blood levels fall with age and that supplementing it extended lifespan in mice, and on population studies linking higher taurine intake to less heart disease.
What supporters point to, and what each source actually shows. None of it is enough to move this letter higher; the trial described above under Evidence wanted is what would.
- Population study, not a trialTaurine levels fell with age in mice, monkeys and people, and taurine extended lifespan in mice. The human part is a measurement of blood levels, not a trial. A 2025 study found taurine levels do not fall consistently with age in people. PMID 37289866
- Population study, not a trialAcross 61 populations in 25 countries, higher taurine excretion, a marker of seafood intake, went with lower heart disease death rates. A comparison of countries, which cannot separate taurine from the rest of the diet. PMID 19239132
A case report describes what happened to one or a few patients. It cannot show the treatment caused the change, and reports of success are published more often than reports of failure.
- A dialysis patient with an inherited mitochondrial disease became more physically active on taurine. A different use from anything graded here. PMID 40237914
Searched PubMed, October 2026: 23 case report record(s) returned. Benefit reports concern inherited mitochondrial diseases. None concerns aging. Reports involving energy drinks or pre-workout products are not about taurine alone and are not listed.
How this letter has changed · latest: October 2026 · Downgraded
Three randomized trials agree on the markers (Moludi et al., Nutr Metab (Lond), 2022; PMID 35870947; Maleki et al., Diabetol Metab Syndr, 2020; PMID 32015761; Li et al., iScience, 2025; PMID 40546935), but adhesion molecules, hs-CRP, TNF-alpha and vascular function are not established stand-ins for a clinical outcome. Applied the written grade definition: the B definition admits a biomarker only when it is an established stand-in for a clinical outcome, such as HbA1c, LDL, blood pressure or bone density, the strict reading the editor confirmed in October 2026.PMID 32015761 PMID 35870947 PMID 40546935
The endothelial and inflammatory marker use in type 2 diabetes rose C to B in October on three randomized trials (PMIDs 35870947, 32015761, 40546935) plus a 2026 pooled analysis; replicated randomized evidence on surrogates is B. The review noted that two trials are Iranian academic trials whose Tabriz cohorts may overlap; independence of groups is the A requirement, not the B one, and the record states the overlap. The glycemic use is C on one null and two positive trials (PMIDs 35870947, 32472292, 32861603), mixed by definition. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).
The acute exercise row said a trial having been run is why the use is Route 2, under a Grade C; the sentence now says the trial found a benefit, which is why the use is C. The aging absence check claimed zero human randomized trials; the re-run query returns 13, and the note now names Van Stijn et al. (2015; PMID 26035756), a week-long perioperative course around hip fracture surgery that reported one-year mortality, null, and Abud et al. (2022; PMID 35700594) and Chupel et al. (2021; PMID 33586039), marker and fitness trials in older women, and explains why none tests the aging claim. Marcangeli et al. (2025; PMID 41061678) added as the observational counterpoint to the taurine-decline premise. Waldron et al. (2018; PMID 29546641) and Deng et al. (2025; PMID 40852891) added as context for the exercise row. The dose field now states 1 g single dose and 2.4 to 3 g/day as studied. All letters unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).PMID 26035756 PMID 29546641 PMID 33586039 PMID 35700594 PMID 40852891 PMID 41061678
The 2023 animal work behind the taurine longevity claim argued that taurine falls with age. Fernandez et al. (Science, 2025; PMID 40472098), from the National Institute on Aging, measured it in three human cohorts, in monkeys and in mice, both in the same individuals over time and across age groups, and found it rose or held steady. The aging use was already D on Route 1, because no human trial has tested taurine against an aging outcome, and it stays D. The record now cites the failed replication alongside the original claim.PMID 40472098
Both type 2 diabetes uses rested on one trial, Moludi et al. (Nutr Metab (Lond), 2022; PMID 35870947; 120 adults), null on fasting glucose and positive on endothelial and inflammatory markers. The search found independent trials on both. Endothelial and inflammatory markers: Maleki et al. (Diabetol Metab Syndr, 2020; PMID 32015761; 50 adults) and Li et al. (iScience, 2025; PMID 40546935; 165 adults, Chongqing, blood pressure, vasodilation and pulse wave velocity) replicate the direction, so a replicated surrogate reaches B. Glycemic control: Maleki et al. (Amino Acids, 2020; PMID 32472292) and Esmaeili et al. (Can J Diabetes, 2021; PMID 32861603), the same Tabriz group at the same 3 g/day dose without a diet, found fasting glucose and HOMA-IR fall, and pooled analyses (Tzang et al., 2024; PMID 38755142; Nie et al., 2026; PMID 41275513) find small reductions; one null and two positive trials is mixed, C. The headline follows the best use. Moved October 2026 by editor adjudication (Arnold Sandlow, D.C.) of a use-specific literature search, every trial re-fetched from PubMed before the letter rose; the search is recorded on the record.PMID 35870947 PMID 32015761 PMID 40546935 PMID 32472292 PMID 32861603 PMID 38755142 PMID 41275513
This record characterized Balshaw et al. (Amino Acids, 2013; PMID 22855206) as Route 2, tested and no benefit. The trial reported the opposite: taurine significantly improved 3-km running time by 1.7%, p=0.013, in a double-blind randomized crossover design in eight trained middle-distance runners. The use is corrected to Grade C, which is what a single unrepeated trial in eight people supports, and the Route 2 designation is removed. The error was first surfaced by this repository's own FINDINGS_2026-08-x30d1.md, which flagged it and correctly declined to change the letter without adjudication.PMID 22855206
A randomized trial of 3 g/day for 8 weeks in 120 adults with type 2 diabetes (PMID 35870947) named fasting blood glucose as a primary outcome and did not improve it, nor HbA1c, nor the lipid profile. Serum insulin and HOMA-IR, secondary outcomes, did improve, as did endothelial and inflammatory markers listed alongside glucose as primary. Glycemic control is filed as D Route 2, tested and not supported on the primary endpoint The one outcome a trial names in advance as its main test. Results on other outcomes carry less weight.. Endothelial and inflammatory markers are filed separately at C. The headline aging grade is unchanged at D Route 1.PMID 35870947
Every change to a letter on this site is dated and published. The full evidence log →
Commercial disclosure
EBL earns no commission on any supplement it grades, and there is no dispensary link on this page to earn one from. Grades are assigned by published rubric before any commercial relationship exists and are never influenced by one. Full disclosure.
No dispensary link. EBL’s practitioner dispensary does not carry this item, so there is nothing to link to. Its absence is not a judgment beyond the letter above.
As studied: 1 g as a single dose about 2 hours before running; 2.4 to 3 g/day in the type 2 diabetes trials. Products commonly supply 0.5 to 3 g/day; up to 6 g/day has been used in some studies.
L-taurine is the standard form. Inexpensive and stable. Found naturally in meat and seafood, vegans/vegetarians have lower baseline levels.
In the type 2 diabetes trial, taurine was given as 1 g three times a day (PMID 35870947); the report does not state whether doses were taken with meals. In the running trial, a single dose was taken about 2 hours before the run (PMID 22855206).
Checked against the full report for 1 of the 2 cited studies, and the published summary for the rest. What the cited trials did, not a schedule. Every supplement, by trial timing →
How to buy this: quality criteria, not a brand
0.5–3g/day.
L-taurine, standard, stable, inexpensive.
USP or any third-party purity seal.
Getting it via energy drinks; proprietary blends; premium pricing on a cheap commodity.
The grade and these criteria are set only from human trials. Any purchase link is convenience and does not affect the grade.
No prominent contraindication at studied doses.
Lithium: taurine alters renal handling of lithium, so levels can shift. The direction reported is not consistent across sources and no human interaction study has settled it, which is itself the reason to involve a prescriber rather than to guess. Antihypertensives: taurine lowers blood pressure modestly, so the effect is additive. Otherwise a low interaction profile.
The additive blood-pressure effect is pooled and real. The record says taurine lowers blood pressure modestly and that the effect is additive with an antihypertensive. The first half is measured: a meta-analysis A study that pools the numbers from several trials into one combined estimate. of oral taurine on resting blood pressure in humans pools the trials and finds reductions in systolic and diastolic pressure. The second half, additivity with a drug, is the usual inference and has not been tested, because the pooled trials were not run in people already on antihypertensives. Someone treated for hypertension should read this as a real but modest effect that has not been measured on top of their medication. Waldron et al. (Curr Hypertens Rep, 2018;20(9):81; PMID 30006901): meta-analysis of the effects of orally administered isolated taurine on resting systolic and diastolic blood pressure in humans.
The lithium claim is thinner than the sentence suggests, and the record already says so. The record states that taurine alters renal handling of lithium, that reported directions disagree, and that no human study has settled it. The search supports the last part strongly. Pairing the two terms with renal handling returns three records in any species, and seven in humans, and none of them administers taurine to a person on lithium; the human hits are about brain amino acid concentrations under chronic lithium, which is the reverse direction, or are unrelated. Lithium has a narrow therapeutic index, so an unmeasured claim about its renal handling is exactly the kind that must not be allowed to firm up through repetition. Basis: pharmacological mechanism, not a human study. Searched PubMed in August 2026: 2 queries, 7 human results.
For a cardiometabolic indication, track the trial-relevant endpoints: home or office blood pressure, fasting glucose/HbA1c, fasting insulin or HOMA-IR when clinically appropriate, and a lipid panel. hs-CRP may be used when relevant. Plasma taurine can document exposure in research but is not a validated clinical efficacy target.
Primary evidence18 papers, each linked to its PubMed record.
Singh et al. (Science, 2023; PMID 37289866): taurine supplementation extended lifespan in worms and mice. It did not extend lifespan in monkeys: the monkey arm gave 250 mg/kg/day for six months and measured healthspan and biomarker outcomes only, with survival never assessed. The human data in that paper is observational (EPIC-Norfolk, roughly 11,966 people) plus an acute exercise experiment. The authors' own conclusion is that clinical trials in humans seem warranted. Yamori et al. (2009; PMID 19239132) and Wójcik et al. (2013; PMID 22322924) are observational associations in humans. Balshaw et al. (Amino Acids, 2013; PMID 22855206) is a randomized crossover trial of a single acute dose on 3-km running performance in trained middle-distance runners. A different question in a different population. Moludi et al. (Nutr Metab (Lond), 2022; PMID 35870947) is an 8-week randomized trial in type 2 diabetes that missed its fasting-glucose primary endpoint, while the endothelial and inflammatory markers named alongside it did improve. Surrogate markers A lab value or measurement used in place of the outcome that matters, such as LDL cholesterol standing in for heart attacks. Moving a surrogate does not always move the outcome., both arms on a low-calorie diet, and not an aging outcome; the marker result has since been replicated by independent groups (below), the glycemic result has not been consistently. The aging claim is D on Route 1: no human randomized trial of taurine supplementation on an aging outcome. Fernandez et al. (Science, 2025; PMID 40472098): circulating taurine increased or stayed unchanged with age in three geographically separate human cohorts, nonhuman primates and mice, longitudinally and cross-sectionally, so the idea that taurine falls with age and that the fall drives aging did not replicate. Observational biomarker work; it carries no grade and does not change the D. Maleki et al. (Amino Acids, 2020; PMID 32472292) and Esmaeili et al. (Can J Diabetes, 2021; PMID 32861603): 8-week randomized trials of 3 g/day in type 2 diabetes from Tabriz, glycemic indices improved. Maleki et al. (Diabetol Metab Syndr, 2020; PMID 32015761): oxidative stress and inflammatory markers improved. Li et al. (iScience, 2025; PMID 40546935): 165 adults with type 2 diabetes in Chongqing, 2.4 g/day for 12 weeks, blood pressure and endothelial function improved. Tzang et al. (Nutr Diabetes, 2024; PMID 38755142) and Nie et al. (Nutr Rev, 2026; PMID 41275513): pooled analyses of taurine on cardiometabolic markers. The aging claim has been checked against the trial literature: Van Stijn et al. (Int J Mol Sci, 2015; PMID 26035756) gave taurine for about a week around hip fracture surgery in older patients and found no effect on in-hospital morbidity or on mortality over the following year, with lower oxidative stress markers; a short perioperative course in a surgical population, it does not test supplementation for aging. Abud et al. (Nutrition, 2022; PMID 35700594): 24 women aged 55 to 70, 1.5 g/day for 16 weeks, oxidative stress markers only. Chupel et al. (Amino Acids, 2021; PMID 33586039): 48 women in their eighties, taurine 1.5 g/day with or without exercise for 14 weeks, inflammatory markers, cognition and fitness; the fitness gains tracked the exercise arms. Marcangeli et al. (Aging Cell, 2025; PMID 41061678): no association between circulating taurine and age, muscle mass, strength or physical performance in 137 men aged 20 to 93, observational, the other side of the taurine-decline premise. For the exercise use, Waldron et al. (Sports Med, 2018; PMID 29546641) pooled 10 studies of oral taurine on endurance performance (Hedges' g 0.40), and Deng et al. (Scand J Med Sci Sports, 2025; PMID 40852891) pooled 23 randomized trials of a single dose (g 0.25, low to very low certainty, no dose-response within 1 to 6 g).
Educational use only · Not medical advice · Starting, stopping or changing any supplement or medication is a decision for your physician
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Who responds: this record's trial reading reports no subgroup that identifies who responds.
This page carries a letter. EBL takes no commission, referral fee or payment of any kind on anything it grades. No letter has been bought and none is for sale.
How this is enforced
That is not a promise, it is a build condition. Two checks run on every deploy: one refuses to publish if a commission is claimed on anything graded, the other refuses if a page names a commercial relationship that is not declared in the register. If either fails, this page does not go live. You can read how the checks work, and what they do not cover, on the evidence integrity page.
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
taurine[tiab] AND (diabetes[tiab] OR diabetic[tiab]) AND (randomized controlled trial[pt] OR meta-analysis[pt]) AND humans[mesh]Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →